About J3 Bioscience
J3 Bioscience develops vaginal health devices for women. Its main product is LIV-Ring, a ring used inside the vagina.
The company is based in Salt Lake City, Utah. Tim Glassett is chief executive officer. DJ Lee serves as chair, co-founder and board director.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | Oct 16, 2026 | $50,000fully sold | 1 | $50,000 | Debt, OptionsRule 506(b) | Form D ↗ |
| Oct 26, 2023 | Oct 27, 2023amended Aug 27, 2026 | $1,726,250of $2.7M target | 23 | $75,054 | Debt, Securities on exerciseRule 506(b) | Form D/A ↗3 earlier filings |
| Jun 5, 2023 | Jun 8, 2023 | $50,000of $1.0M target | 1 | $50,000 | EquityRule 506(b) | Form D ↗ |
| Mar 2, 2022 | Mar 7, 2022amended Nov 16, 2022 | $316,815of $1.0M target | 6 | $52,803 | Equity, OptionsRule 506(b) | Form D/A ↗2 earlier filings |
| Apr 29, 2021 | May 12, 2021 | $530,000of $600K target | 5 | $106K | EquityRule 506(b) | Form D ↗ |
| Jul 21, 2020 | Jul 30, 2020 | $605,000of $1.0M target | 3 | $201K | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Dec 17, 2019 | Dec 19, 2019 | $20,000of $500K target | 1 | $20,000 | EquityRule 506(b) | Form D ↗ |
| Mar 18, 2019 | Mar 21, 2019 | $22,500of $600K target | 1 | $22,500 | Equity, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Mar 3, 2018 | Mar 8, 2018amended Dec 3, 2018 | $420,000of $900K target | 5 | $84,000 | Debt, Options, Securities on exerciseRule 506(b) | Form D/A ↗1 earlier filing |
| Aug 22, 2016 | Dec 12, 2016amended Aug 28, 2017 | $937,000of $1.5M target | 25 | $37,480 | EquityRule 506(b) | Form D/A ↗2 earlier filings |
| Dec 31, 2013 | Nov 23, 2015 | $1,054,132of $1.1M target | 31 | $34,004 | DebtRule 506(b) | Form D ↗ |
| Nov 16, 2012 | Nov 29, 2012 | $540,500of $750K target | 10 | $54,050 | Equity06 | Form D ↗ |
| Total, 12 offerings | $6,272,197 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed J3 Bioscience
J3 Bioscience develops vaginal rings for women’s health. Its investment case centers on a patented platform rather than one device use. The product combines long-acting delivery with a design focused on comfort. The central test is whether the platform can support more treatments.
The problem it targets
J3 Bioscience argues that women’s therapies should work with female biology rather than against it. That view points to delivery methods tailored to women, not a general-purpose device. The company identifies comfort as part of the need it wants to address.
What the product does
LIV-Ring is a patented ring placed inside the vagina. It is designed to deliver therapies in a controlled way over longer periods. The company positions the ring as a platform for multiple women’s health treatments.
Progress so far
J3 Bioscience announced LivRing’s commercial launch on September 18, 2024. On November 10, 2025, it announced a collaboration to study LIV-Ring. The sequence moved the company from initial commercialization toward additional study work.
We wrote this summary from public statements by J3 Bioscience and its investors. It is not investment advice.
J3 Bioscience in the News
Leadership Team
Executive officers and directors listed on J3 Bioscience's Form D filed Oct 16, 2026.
Earlier filings also listed Jayne Carney (director, last listed Jun 2023), Larry Rigby (director, last listed May 2021) and James Herrin (executive officer, last listed Nov 2012).
Sources
- SECJ3 BIOSCIENCE, INC. Form D/A, filed Jun 23, 2025
- SECJ3 BIOSCIENCE, INC. Form D/A, filed Jan 31, 2025
- SECJ3 BIOSCIENCE, INC. Form D, filed Oct 27, 2023
- SECJ3 BIOSCIENCE, INC. Form D/A, filed Oct 21, 2022
- SECJ3 BIOSCIENCE, INC. Form D, filed Mar 7, 2022
- SECJ3 BIOSCIENCE, INC. Form D, filed Mar 8, 2018
- SECJ3 BIOSCIENCE, INC. Form D/A, filed Mar 2, 2017
- SECJ3 BIOSCIENCE, INC. Form D, filed Dec 12, 2016
- SECJ3 BIOSCIENCE, INC. filing history
- CompanyAbout
- CompanyJ3 Bioscience Announces Collaboration to Study LIV-Ring
- PressJ3 Bioscience Announces Commercial Launch of LivRing